Medication associated with weight gain may influence outcome in a weight management program

Annals of Pharmacotherapy

Volumn 39, Issue 7-8, 2005, Pages 1204-1208

  Malone, Margaret ^a   Alger Mayer, Sharon A ^b   Anderson, Drew A ^c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Diabetes; Obesity; Weight gain drugs

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHISTAMINIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CORTICOSTEROID; CYPROHEPTADINE; GABAPENTIN; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; INSULIN; LITHIUM; MEGESTROL ACETATE; NISOLDIPINE; NIZATIDINE; ORAL CONTRACEPTIVE AGENT; PHENELZINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; STEROID; SULFONYLUREA DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ADULT; ARTICLE; BODY MASS; DEPRESSION; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AGED; BEHAVIOR THERAPY; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; OBESITY; PHARMACEUTICAL PREPARATIONS; PRESCRIPTIONS, DRUG; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 21744449490     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E434     Document Type: Article

References (16)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-7.
2. The practical guide, identification, evaluation, and treatment of overweight and obesity in adults. NIH Publication #00-4084. National Heart, Lung and Blood Institute, North American Association for the Study of Obesity. October 2000. www.nhlbi.nih.gov/nhlbi/nhlbi.htm (accessed 2005 Apr 25).
3. McGuire MT, Wing RR, Hill JO. The prevalence of weight loss maintenance among American adults. Int J Obes 1999;23:1314-9.
4. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002;346:591-602.
5. Steptoe A, Kerry S, Rink E, Hilton S. The impact of behavioral counseling on stage of change in fat intake, physical activity and cigarette smoking in adults at increased risk of coronary heart disease. Am J Public Health 2001;91:265-9.
6. Cheskin LJ, Bartlett SJ, Zayas R, Twilley CH, Allison DB, Contoreggi C. Prescription medications: a modifiable contributor to obesity. South Med J 1999;92:898-904.
7. Allison DB, Mentore JL, Mooseong H, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
8. Lean MEJ, Pajonk FG. Patients on atypical antipsychotic drugs. Diabetes Care 2003;26:1597-605.
9. The Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995;18:1415-27.
10. UK Intensive Diabetes Study (UKIDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53.
11. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Diabetes Care 1997;20:1744-66.
12. Brownell KD. The LEARN Program for weight management 2000. Dallas: American Health Publishing Company, 2000.
13. Blair SN, Dunn AL, Marcus BH, Carpenter RA, Jaret P. Active living everyday. In: Drews CM, ed. Human Kinetics. Champaign, IL: Human Kinetics Publishers; 2001.
14. Wing RR,Venditti E, Jakicic JM, Polley BA, Lang W. Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care 1998;21:350-9.
15. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
16. Diabetes Prevention Program Research Group. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obes Res 2004;12:1426-35.